Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic nonsmall-cell lung cancer in Greece: A cost-minimization analysis

Annals of Oncology

Volumn 21, Issue 7, 2009, Pages 1462-1467

  Maniadakis, N ^a   Fragoulakis, V ^a   Pallis, A G ^b   Simou, E ^a   Georgoulias, V ^b  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Cisplatin; Docetaxel; Economic evaluation; Gemcitabine; Lung cancer; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DIURESIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; GREECE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HYDRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; FEMALE; GREECE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 77954299993     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp551     Document Type: Article

References (27)

1. Ginsberg RJ, Vokes EE, Raben A. Non small cell lung cancer. In DeVita VT, Hellman S, Rosenberg SA (eds): Principles and Practice in Oncology, 5th edition. Philadelphia, PA: Lippincott-Raven 1997; 858-911.
2. Greelee RT, Murray T, Bolden S, Windo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
3. Feigal EG, Christian M, Cheson B et al. New chemotherapeutic agents in nonsmall-cell lung cancer. Semin Oncol 1993; 20(2): 185-201.
4. Souquet PJ, Chauvin F, Boissel JP et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993; 342(8862): 19-21.
5. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-smallcell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909.
6. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9(9): 1618-1626.
7. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12(2): 360-367.
8. Comella P, Frasci G, Panza N et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000; 18(7): 1451-1457.
9. Kelly K, Crowley J, Bunn PA et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19(13): 3210-3218.
10. Scagliotti GV, De MF, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20(21): 4285-4291.
11. Georgoulias V, Papadakis E, Alexopoulos A. Platinum-based and non-platinumbased chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357(9267): 1478-1484.
12. Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002; 20(17): 3578-3585.
13. Georgoulias V, Ardavanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005; 23(13): 2937-2945.
14. Georgoulias V, Ardavanis A, Agelidou A et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 2004; 22(13): 2602-2609.
15. Maniadakis N, Fragoulakis V, Pectasides D, Fountzilas G. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res Opin 2009; in press.
16. Maniadakis N, Pallis A, Fragoulakis V et al. Economic analysis of a multicentre, randomized phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. Curr Med Res Opin 2007; 23: 2251-2257.
17. Fountzilas G, Kalofonos HP, Dafni U et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004; 15: 1517-1526.
18. Lees M, Aristides M, Maniadakis N et al. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20: 325-337.
19. Aristides M, Lees M, Botwood N et al. Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. Eur J Health Econ 2003; 4: 216-221.
20. Jiang H, Zhou XH. Bootstrap Confidence Intervals for Medical Costs With Censored Observations. UW Biostatistics Working Paper Series, University of Washington 2003; Paper 202.
21. Lin DY. Linear regression analysis of censored medical costs. Biostatistics 2000; 1(1): 35-47.
22. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika 2000; 87: 329-343.
23. Fenn P, McGuire A, Phillips V et al. The analysis of censored treatment cost data in economic evaluation. Med Care 1995; 33: 851-863.
24. Carides GW, Heyse JF, Iglewicz B. A regression-based method for estimating mean treatment cost in the presence of right-censoring. Biostatistics 2000; 1: 299-313.
25. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
26. Raikou M, McGuire A. Parametric estimation of medical care costs under conditions of censoring. The London School of Economics and Political Science, Working paper No. 13/2009, London WC2A 2AE, England.
27. Hutson AD. Analytical bootstrap methods for censored data. J Appl Math Decis Sci 2002; 6(2): 129-141.